REAL-WORLD EVIDENCE SOLUTIONS

An RWE ecosystem for commercial and clinical success

MEET THE FUTURE OF REAL-WORLD INSIGHTS IN CANCER

2

CHALLENGES

Cancer and its ComplexityDiscovering and assessing cancer therapies demands the best insights into disease etiology, treatment, impact, and outcomes. Robust analyses must account for the specific interests of all stakeholders and a variety of issues across the spectrum of cancers.

• Clinicians facing highly sophisticated treatment decisions and patient stratification

• Payers wanting more proof of value as innovations challenge stretched budgets

• Pharma generating more innovative evidence

• Patients and caregivers impacting therapeutic options

• Increasing role of advocacy groups in awareness building and data generation

3www.imshealth.com/rwe

HOLISTIC APPROACH

IMS RWE Cancer Ecosystem

Creating a common foundation of the right oncology real-world data (RWD) to address the cancer-related needs of your entire organization

IMS Health combines anonymous patient data with advanced analytics, powerful processing, and deep scientific and commercial expertise to deliver credible, breakthrough oncology insights.

4

IMS RWE CANCER ECOSYSTEM

Multi-source data representing macro-to-patient-level RWD

Comprehensive, Global Cancer Data

Innovative and client-centric technology solutions

Technology-Enabled Analytics

Delivered by a global, dedicated team, including tumor-specific specialists

Expertise-Driven Oncology Services

Unparalleled Oncology Capabilities

5www.imshealth.com/rwe

• Comprehensive cross-sectional survey data

- Coverage of 25+ primary cancers across 15+ markets

- 200,000+ patient histories per year from 4,000+ specialists

• IMS MIDAS sales data integration

• Primary data collection from specialists and patients

• Promotional data

• More than 10 years of data from 15+ million anonymous cancer patients

- EMR data

- Medical claims data

- Hospital data

- Prescription data

- Consumer data

- Biomarker and genomic alteration data

• Largest, most comprehensive cancer platform commercially available in the USA

• EMR extraction capabilities in Europe

• Predictive analytics algorithms

• Intelligent data interfaces and visualization

• Data-linking technologies designed to protect privacy

• Disease, patient, and therapy understanding

• R&D targeting and efficiency

• Market access strategies

• Real-world value demonstration, including HEOR, pharmacoepidemiology, and drug safety

• Commercial positioning, planning, and performance tracking

6

UNIQUE APPROACH TO DATA

Partnering for Richer Data to Support Precision Therapy

• Granular understanding of the comprehensive patient pathway

• Insights into differences in unmet needs, treatment use, cost, and outcomes among different genomic subpopulations

• Evaluation of targeted therapies, based on unique molecular drivers of individual cancers

The IMS Health and Foundation Medicine collaboration enables unique linkage of biomarker data with other sources of RWD such as payer claims and oncology EMR at an anonymous patient level. This provides an unprecedented evidence base for improved medical-scientific and commercialization strategies.

Biomarker Duration of Therapy

Median Days on Erlotinib Therapy (linked cohort n=152)

Source: IMS Health retrospective analysis of IMS RWD Pharmacy Prescription and Medical Claims linked to Foundation Medicine molecular profiling data

107

365

115

312

135

358

EGFR- EGFR+ EGFR+Exon

20 mut

EGFR+non-Exon

20 mut

KRAS+ KRAS-

7www.imshealth.com/rwe

CUSTOM RWD SOLUTIONS

Sourcing and Linking Expertise for T-Shaped Evidence NetworksStrategic Data Sourcing

• Enhance existing RWD through custom sourcing support to extract data and create custom datasets

• Identify and access new data sources addressing specific research needs, also in niche markets

• Benefit from IMS RWD Catalogue of 2,200+ data sources globally, including 40%+ in oncology

Data Linkage

• Understand the full patient pathway through integrating datasets at the record level (e.g., USA and Scandinavia)

• Gain deeper insights by sales indication through integration with IMS MIDAS sales data

T-Shaped Evidence Networks

Broad

Deep

Ra

ng

e o

f D

ata

Typ

es

Population Coverage

Nationally relevant databases

Augmented datasets

Biobank, labs, registries

IMS Health T-shaped Evidence Networksaddress the need to consider both breadthand depth of RWD when accessing the mostappropriate fact base

8

IMS Health has established excellence in global and local cancer-related research in mature and emerging markets.

Proven Approach: We have a track record of successful HTA submissions, published findings, and EMA-accepted Drug Utilization Studies in multiple therapy areas and geographies. Our bibliography comprises more than 3,500 publications, with 520+ in solid and liquid tumors.

Quality Systems: Our leading Quality Management System includes electronic control of standards, audit trail, and computer system validation.

Credible Solutions: Our databases and methods have been validated in peer-reviewed publications and are used by academics and authorities. They serve as part of a framework for safety assessment and for regulatory purposes.

OUR SCIENTIFIC COMMITMENT

Bringing Scientific Credibility and Quality to All Our Work

9www.imshealth.com/rwe

SERVICES

Helping StakeholdersAll functions can derive value through a shared view of what is happening in real-life healthcare settings.

• Launch pricing support

• Tumor-specific forecasting

• Ongoing value differentiation

• Launch/promotion planning

• Segmentation and targeting

• Cancer patient journeys

Commercial

• Drug utilization/monitoring

• Rigorous and efficient tumor modeling

• EMR-enabled outcomes research

• Local burden of illness/disease

• Adverse event/signal detection

• Regulatory submissions and responses

HEOR, Pharmacoepidemiology,and Drug Safety

• Custom data sourcing

• E360TM technology suite

• Evidence platforms

• T-shaped Cancer Evidence Networks

RWE Platform Developers

• Translational research

• Drug pathways

• Target population/product profile

• Trial and recruitment feasibility

R&D

10

EVIDENCE PLATFORM

IMS RWD Oncology US Platform

• More than 10 years of data from 15+ million anonymous cancer patients

Our comprehensive cancer data platform links multiple data types, including EMRs, across settings of care.

R&DPredictive

Analytics Tools

Medical-ScientificStudies/

Publications

HEORForecasting &

KOL Engagement

CommercialPatient

Analytics

Software Application(e.g., E360TM, SAS, R, Tableau)

Platform Core

Deep Clinical Data

(e.g., Genomics Data)

Enriched Data (e.g., NLP,

Linkage, Local Registry)

Broad, Nationally Relevant Databases (e.g., IMS RWD Claims Data)

Augmented Datasets (e.g., Oncology EMR)

• Data Integration• Data Hosting• Business Rules & Analytical Methods• Ongoing Data Governance

T-Shaped Portfolioof Data Sources

Services & Engagement

Technology- Enabled Analytics

Real-World Data

• Geographically representative of the USA to enable a projectable base

• Integrates biomarker, histology, consumer, and other patient datasets

11www.imshealth.com/rwe

HOW WE HELP

Enhancing RCT Results with RWE

OUR CHALLENGE

Help our client determine whether the rate and timing of hemoglobin (Hb) decline in cancer patients receiving chemotherapy seen in pooled RCT was representative of the real world.

OUR RESULTS

Our analysis verified the RCT findings, increasing payer confidence in those clinical results. This approach can help support future launch strategies when there is uncertainty regarding the applicability of RCT results to real-life settings.

OUR SOLUTION

We analyzed pooled data from six RCTs and replicated the analysis using our US community oncology clinic EMR database.

440 Patients

5,922Additional patient experiences analyzed

IMS Health Real-World Evidence SolutionsUncovering insights from real-world data to improve decision making and patient outcomes

©2016 IMS Health Incorporated and its affiliates. All rights reserved. IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are trademarks of IMS Health Incorporated.

IMS RWD Oncology DynamicsThe latest addition to the IMS Health cross-sectional survey portfolio

CONTACT US FOR MORE INFORMATION

The Americas

One IMS Drive

Plymouth Meeting, PA 19462

USA

Tel: +1 484 567 6461

Europe

210 Pentonville Road

London, N1 9JY

United Kingdom

Tel: +44 (0) 20 3075 4800

rweinfo@imshealth.com

www.imshealth.com/rwe

www.linkedin.com/company/ims-health-real-world-evidence

www.twitter.com/IMSHealthRWE

• New global study covering all key tumor types, stages, and lines of therapy

• Large physician panel with high patient sample sizes

• Facilitates understanding of cancer treatment paradigms

• Modern, web-based analytical tool to gain immediate insights

NEW IN 2016!

IMS HEALTHREAL-WORLD

EVIDENCESOLUTIONS

ALK Status

Key Cancer: Patient Count NSCLC: Line of Therapy

1st

2nd

AwaitingResults

Wild

Mutant

0 100 200 300

NSCLCCOLORECTAL

BREASTALL OTHERS

PROSTATENHL

PANCREASKIDNEY

OVARIANCLL

BLADDERCML

STOMACHSCLCAML

MELANOMA

KEY CANCER

Count (Patient-ID)

NotTested

NSCLC

3rd+

Patient ProfileIMS RWD Oncology Dynamics

https://websolutions.imshealth.com/EB2/User/CustomerLogin